Evidence map›Paper›PMID 39052735›Full record

ArticleThe Journal of infectious diseases2024

Evidence of Reduced Virulence and Increased Colonization Among Pneumococcal Isolates of Serotype 3 Clade II Lineage in Mice.

Ognjen Sekulovic, Caitlyn Gallagher, Jonathan Lee, Li Hao, Stavros Zinonos, Charles Y Tan, Annaliesa Anderson, Isis Kanevsky

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ognjen SekulovicPfizer Inc, Bacterial Vaccines and Technology, Pearl River, New York.ORCID 0000-0003-1006-0595
Caitlyn GallagherPfizer Inc, Bacterial Vaccines and Technology, Pearl River, New York.
Jonathan LeePfizer Inc, Bacterial Vaccines and Technology, Pearl River, New York.
Li HaoPfizer Inc, Bacterial Vaccines and Technology, Pearl River, New York.
Stavros ZinonosPfizer Inc, Bacterial Vaccines and Technology, Pearl River, New York.
Charles Y TanPfizer Inc, Early Clinical Development, Collegeville, Pennsylvania.
Annaliesa AndersonPfizer Inc, Bacterial Vaccines and Technology, Pearl River, New York.
Isis KanevskyPfizer Inc, Bacterial Vaccines and Technology, Pearl River, New York.

Funding

Division of Worldwide Research and Development, Pfizer, Inc
6 · The paper itself

Abstract

Recent phylogenetic profiling of pneumococcal serotype 3 (Pn3) isolates revealed a dynamic interplay among major lineages with the emergence and global spread of a variant termed clade II. The cause of Pn3 clade II dissemination along with epidemiological and clinical ramifications are currently unknown. Here, we sought to explore biological characteristics of dominant Pn3 clades in a mouse model of pneumococcal invasive disease and carriage. Carriage and virulence potential were strain dependent with marked differences among clades. We found that clinical isolates from Pn3 clade II are less virulent and less invasive in mice compared to clade I isolates. We also observed that clade II isolates are carried for longer and at higher bacterial densities in mice compared to clade I isolates. Taken together, our data suggest that the epidemiological success of Pn3 clade II could be related to alterations in the pathogen's ability to cause invasive disease and to establish a robust carriage episode.

Indexed as

Carrier StatePneumococcal InfectionsSerogroupStreptococcus pneumoniaeAnimalsDisease Models, AnimalFemaleHumansMicePhylogenyVirulencecarriageclade IIserotype 3Streptococcus pneumoniaevirulence

Identifiers

PMID39052735
PMCPMC11272092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.